Clinical trial NCT06823167: A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Official title: A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Solid Malignancies
Hematologic Malignancies
Lead sponsor: Immunome, Inc.
Sponsor class: INDUSTRY
First posted: 2025-02-12
Enrollment: 117
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.

Detailed description: IM-1021-101 is a 2-part Phase 1 first-in-human (FIH), open-label, multicenter dose escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of the ROR1 directed antibody-drug conjugate (ADC) IM-1021. IM-1021 will be administered to participants with advanced B-cell lymphomas and advanced solid tumors. Part A of the study is a dose escalation phase to evaluate safety and tolerability of IM-1021 and to determine recommended doses for further development. IM-1021 will be administered intravenously on an intermittent basis. The safety and tolerability of escalating doses of IM-1021 will be evaluated. Alternative dosing schedules may also be evaluated. Part B of the study is an expansion phase to further evaluate safety and tolerability of IM-1021 at candidate recommended doses in indication specific cohorts of participants. The safety and preliminary efficacy endpoints of this study will inform a preliminary risk-benefit assessment of IM-1021 in this patient population.

Eligibility criteria: Inclusion Criteria:

1. Informed consent signed by the participant prior to conducting study-specific procedures
2. ≥18 years of age
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
4. Histological or cytological diagnosis of:

   Part A: advanced B-cell lymphomas or solid tumors, of the following subtypes:

   B-cell Lymphomas:
   * Mantle cell lymphoma (MCL)
   * Diffuse large B-cell lymphoma (DLBCL) (including Richter's transformation)
   * Follicular lymphoma
   * Small lymphocytic lymphoma (SLL)

   Solid Tumors:
   * Pancreatic cancer
   * Non-squamous non-small cell lung cancer (NSCLC)
   * Malignant mesothelioma
   * Epithelial ovarian cancer. Participants with fallopian tube and/or peritoneal malignancies are also eligible.
   * Triple-negative breast cancer.
   * Liposarcoma

   Other, unlisted histologies, if approved by the Sponsor Medical Monitor

   Part B Cohorts B1, B2, and B3:

   Histological or cytological diagnosis of the cohort-specific disease indication. Indications may include those listed in Inclusion Criterion 4.a
5. Participants must have adequate organ function.
6. Participants must have a negative pregnancy test, be willing to practice highly effective methods of birth control, use condoms, and refrain from oocyte/sperm donation, as applicable, as detailed in the protocol.
7. Participants must be refractory to or have relapsed after at least one prior standard therapeutic regimen. Participants must be relapsed or refractory to, have developed an intolerance to, or not be candidates for available therapies with established benefit. Participants with B-cell malignancies should have received at least two lines of therapy, including available therapies with established benefit. Participants with SLL should have received at least three prior lines of therapy.
8. Participants must have measurable disease as per the relevant response assessment framework: Lugano Classification for lymphoma (except SLL) , per iwCLL criteria for SLL , and per RECIST v.1.1 for solid tumors.

Exclusion Criteria:

1. Previously treated with an ADC with a topoisomerase-1 inhibitor payload.
2. Previously received a ROR1-targeted therapy (eg, ADC, cell therapy, or monoclonal antibody).
3. History of an anaphylactic reaction to irinotecan or ≥ grade 3 GI toxicity to prior irinotecan.
4. Life expectancy \< 12 weeks.
5. Prior solid organ transplant.
6. Participants with symptomatic ascites or pleural effusion. Participants who are clinically stable for at least 2 weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis or catheter) are eligible.
7. Participant has a known active central nervous system (CNS) primary tumor or metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to study entry, have no radiological evidence of new or enlarging brain metastases, and are off steroids or on a stable dose up to an equivalent of prednisone 10 mg/day for at least 15 days prior to first dose of study medication. Participants who have symptoms consistent with CNS metastasis must have a negative magnetic resonance imaging (MRI) during the screening period.
8. Participant has a known history of malignant primary brain tumor, or another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially curative therapy with no evidence of that disease for at least 2 years. Exception: The time requirement does not apply to participants who underwent successful definitive resection of certain cancers.
9. Participant has certain other significant medical conditions including cardiac, pulmonary, and infectious disease as detailed in the protocol.
10. Participant is pregnant, breastfeeding, or expecting to conceive within the projected duration of the study.

Primary outcomes:
measure: Safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)
timeFrame: From first dose to 37 days following last dose of study treatment
measure: Determine the recommended dose(s) and schedule(s) of IM-1021 for further development
timeFrame: From first dose to 37 days following last dose of study treatment
Secondary outcomes:
measure: Area under the concentration-time curve (AUC) of IM-1021 in participants with advanced lymphomas and advanced solid tumors
timeFrame: Through 30-37 days following last dose of IM-1021 up to end of study
measure: Concentration at end of infusion (Ceoi) of IM-1021 in participants with advanced lymphomas and advanced solid tumors
timeFrame: Through 30-37 days following last dose of IM-1021 up to end of study
measure: Maximum observed concentration (Cmax) of IM-1021 in participants with advanced lymphomas and advanced solid tumors
timeFrame: Through 30-37 days following last dose of IM-1021 up to end of study
measure: Time to maximum observed concentration (Tmax) of IM-1021 in participants with advanced lymphomas and advanced solid tumors
timeFrame: Through 30-37 days following last dose of IM-1021 up to end of study
measure: Trough Concentration of IM-1021 in participants with advanced lymphomas and advanced solid tumors
timeFrame: Through 30-37 days following last dose of IM-1021 up to end of study
measure: Apparent Terminal Half-Life (t1/2) of IM-1021 in participants with advanced lymphomas and advanced solid tumors
timeFrame: Through 30-37 days following last dose of IM-1021 up to end of study
measure: Characterize the immunogenicity of IM-1021
timeFrame: From first dose to about 30 days following last dose of study treatment
measure: To evaluate the preliminary anti-tumor activity of IM-1021 in participants with advanced lymphomas and advanced solid tumors
timeFrame: Week 6 until disease progression or participant discontinuation from study
measure: To evaluate the preliminary anti-tumor activity of IM-1021 in participants with advanced lymphomas and advanced solid tumors
timeFrame: Week 6 until disease progression or participant discontinuation from study
measure: To evaluate the preliminary anti-tumor activity of IM-1021 in participants with advanced lymphomas and advanced solid tumors
timeFrame: Week 6 until disease progression or participant discontinuation from study
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City Of Hope
state: California
city: Grand Rapids
country: United States
facility: START Midwest
state: Michigan
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
city: Irving
country: United States
facility: NEXT Oncology
state: Texas
Study officials:
References: